1
|
Bunting ST, Oldaker T, Qualtieri J, O'Donahue M, Maremont S, Harricharran H, Kelliher A, Kdouh L, Devitt K, Cherian S, Stetler-Stevenson M, Moore J. ICCS Women in Cytometry-Impact 10 years later: A call to promote gender equity. Cytometry B Clin Cytom 2020; 100:282-284. [PMID: 32830879 DOI: 10.1002/cyto.b.21942] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/10/2020] [Revised: 07/02/2020] [Accepted: 07/20/2020] [Indexed: 11/06/2022]
Affiliation(s)
- Silvia T Bunting
- Department of Pathology, Cleveland Clinic Florida, Weston, Florida, USA
| | - Teri Oldaker
- Oldaker Consulting, San Clemente, United States, USA
| | - Julianne Qualtieri
- Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | | | - Sara Maremont
- Sonora Quest Laboratories/Laboratory Sciences of Arizona, Phoenix, AZ, USA
| | | | | | | | - Katherine Devitt
- University of Vermont Medical Center/Larner College of Medicine at the University of Vermont, Burlington, VT, USA
| | - Sindhu Cherian
- Department of Laboratory Medicine, University of Washington, Seattle, WA, USA
| | | | - Jonni Moore
- Pathology and Laboratory Medicine, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA, USA
| |
Collapse
|
2
|
Wang Z, Vaughan TY, Zhu W, Chen Y, Fu G, Medrzycki M, Nishio H, Bunting ST, Hankey-Giblin PA, Nusrat A, Parkos CA, Wang D, Wen R, Bunting KD. Gab2 and Gab3 Redundantly Suppress Colitis by Modulating Macrophage and CD8 + T-Cell Activation. Front Immunol 2019; 10:486. [PMID: 30936879 PMCID: PMC6431666 DOI: 10.3389/fimmu.2019.00486] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2018] [Accepted: 02/22/2019] [Indexed: 12/13/2022] Open
Abstract
Inflammatory Bowel Disease (IBD) is a multi-factorial chronic inflammation of the gastrointestinal tract prognostically linked to CD8+ T-cells, but little is known about their mechanism of activation during initiation of colitis. Here, Grb2-associated binding 2/3 adaptor protein double knockout mice (Gab2/3−/−) were generated. Gab2/3−/− mice, but not single knockout mice, developed spontaneous colitis. To analyze the cellular mechanism, reciprocal bone marrow (BM) transplantation demonstrated a Gab2/3−/− hematopoietic disease-initiating process. Adoptive transfer showed individual roles for macrophages and T-cells in promoting colitis development in vivo. In spontaneous disease, intestinal intraepithelial CD8+ but much fewer CD4+, T-cells from Gab2/3−/− mice with rectal prolapse were more proliferative. To analyze the molecular mechanism, reduced PI3-kinase/Akt/mTORC1 was observed in macrophages and T-cells, with interleukin (IL)-2 stimulated T-cells showing increased pSTAT5. These results illustrate the importance of Gab2/3 collectively in signaling responses required to control macrophage and CD8+ T-cell activation and suppress chronic colitis.
Collapse
Affiliation(s)
- Zhengqi Wang
- Division of Hem/Onc/BMT, Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, GA, United States
| | - Tamisha Y Vaughan
- Division of Hem/Onc/BMT, Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, GA, United States
| | - Wandi Zhu
- Division of Hem/Onc/BMT, Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, GA, United States
| | - Yuhong Chen
- BloodCenter of Wisconsin, Milwaukee, WI, United States
| | - Guoping Fu
- BloodCenter of Wisconsin, Milwaukee, WI, United States
| | - Magdalena Medrzycki
- Division of Hem/Onc/BMT, Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, GA, United States
| | - Hikaru Nishio
- Department of Pathology, Emory University, Atlanta, GA, United States
| | - Silvia T Bunting
- Department of Pathology, Children's Healthcare of Atlanta, Atlanta, GA, United States
| | - Pamela A Hankey-Giblin
- Department of Veterinary Science, Pennsylvania State University, University Park, PA, United States
| | - Asma Nusrat
- Department of Pathology, Emory University, Atlanta, GA, United States.,Department of Pathology, University of Michigan, Ann Arbor, MI, United States
| | - Charles A Parkos
- Department of Pathology, Emory University, Atlanta, GA, United States.,Department of Pathology, University of Michigan, Ann Arbor, MI, United States
| | - Demin Wang
- BloodCenter of Wisconsin, Milwaukee, WI, United States
| | - Renren Wen
- BloodCenter of Wisconsin, Milwaukee, WI, United States
| | - Kevin D Bunting
- Division of Hem/Onc/BMT, Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, GA, United States
| |
Collapse
|
3
|
Chonat S, McLemore ML, Bunting ST, Nortman S, Zhang K, Kalfa TA. Congenital dyserythropoietic anaemia type I diagnosed in a young adult with a history of splenectomy in childhood for presumed haemolytic anaemia. Br J Haematol 2018; 182:10. [DOI: 10.1111/bjh.15217] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Satheesh Chonat
- Department of Pediatrics; Haematology/Oncology; Emory University; School of Medicine and Aflac Cancer and Blood Disorders Center; Children's Healthcare of Atlanta; Atlanta GA USA
| | - Morgan L. McLemore
- Department of Hematology and Medical Oncology; Winship Cancer Institute of Emory University School of Medicine; Atlanta GA USA
| | - Silvia T. Bunting
- Department of Pathology; Children's Healthcare of Atlanta; Emory University School of Medicine; Atlanta GA USA
| | - Shannon Nortman
- Molecular Genetics; Cincinnati Children's Hospital Medical Center; Cincinnati OH USA
| | - Kejian Zhang
- Molecular Genetics; Cincinnati Children's Hospital Medical Center; Cincinnati OH USA
| | - Theodosia A. Kalfa
- Hematology, Cincinnati Children's Hospital Medical Center; Cincinnati OH USA
- Department of Pediatrics; University of Cincinnati; College of Medicine; Cincinnati OH USA
| |
Collapse
|
4
|
Bunting CT, Senior T, Susson Y, Rivera A, Saxe D, Bunting ST. Utility of Fluorescence In Situ Hybridization Panel for Myelodysplastic Syndrome in Evaluation of Cytopenia in a Pediatric Hospital: A 5-Year Retrospective Review and Utilization Management. Lab Med 2017; 48:266-270. [PMID: 28934515 DOI: 10.1093/labmed/lmx047] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Background MDS FISH was routinely ordered together with chromosome analysis for patients with cytopenia in our hospital. The utility of MDS FISH in the pediatric population is unknown. Objective To analyze the utility of fluorescence in situ hybridization panel for myelodysplastic syndrome (MDS FISH) in the management of patients with cytopenia. Methods We performed a retrospective review over a 5-year period, from 2009 to 2014 to determine whether chromosome analysis (CA) plus MDS FISH added useful information compared to chromosome analysis alone. Both CA and MDS FISH were performed on 253 bone marrow biopsies from 182 patients. Results CA was highly correlated with MDS FISH (P < .0001) and detected all of the abnormalities seen by MDS FISH in 93.7% of the cases. CA is less expensive and detects additional chromosomal abnormalities not tested in the myelodysplastic syndrome panel. We propose MDS FISH should be ordered when CA fails to give adequate results.
Collapse
Affiliation(s)
| | - Tal Senior
- Business Intelligence, Children's Healthcare of Atlanta, GA
| | - Yehuda Susson
- Business Intelligence, Children's Healthcare of Atlanta, GA
| | - Alethia Rivera
- Department of Pathology, Children's Healthcare of Atlanta, GA
| | - Debra Saxe
- Department of Pathology, Emory University School of Medicine, Atlanta, GA
| | - Silvia T Bunting
- Department of Pathology, Children's Healthcare of Atlanta, GA.,Department of Pathology, Emory University School of Medicine, Atlanta, GA
| |
Collapse
|
5
|
Mitchell SG, Bunting ST, Saxe D, Olson T, Keller FG. A variant c-KIT mutation, D816H, fundamental to the sequential development of an ovarian mixed germ cell tumor and systemic mastocytosis with chronic myelomonocytic leukemia. Pediatr Blood Cancer 2017; 64. [PMID: 27781377 DOI: 10.1002/pbc.26282] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/16/2016] [Revised: 08/11/2016] [Accepted: 09/05/2016] [Indexed: 11/06/2022]
Abstract
An activating point mutation of the c-KIT tyrosine kinase receptor gene, D816H, has been described in germ cell tumors (GCTs). We report an adolescent diagnosed with an ovarian mixed GCT and systemic mastocytosis with chronic myelomonocytic leukemia (SM-CMML). The teratoma and dysgerminoma differed by copy number aberrations via single nucleotide polymorphism (SNP) microarray, but were inclusive of the same c-KIT D816H point mutation (c.2446G>C) also identified in blood and bone marrow mast cells. These findings indicate not only a clonal origin of the GCT and hematologic malignancy, but also suggest a rare KIT mutation may be playing a fundamental role in malignancy development.
Collapse
Affiliation(s)
- Sarah G Mitchell
- Department of Pediatric Hematology/Oncology, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, Georgia
| | - Silvia T Bunting
- Department of Pathology, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, Georgia
| | - Debra Saxe
- Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia
| | - Thomas Olson
- Department of Pediatric Hematology/Oncology, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, Georgia
| | - Frank G Keller
- Department of Pediatric Hematology/Oncology, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, Georgia
| |
Collapse
|
6
|
Dong L, Yu WM, Zheng H, Loh ML, Bunting ST, Pauly M, Huang G, Zhou M, Broxmeyer HE, Scadden DT, Qu CK. Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment. Nature 2016; 539:304-308. [PMID: 27783593 DOI: 10.1038/nature20131] [Citation(s) in RCA: 185] [Impact Index Per Article: 23.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2015] [Accepted: 09/29/2016] [Indexed: 12/18/2022]
Abstract
Germline activating mutations of the protein tyrosine phosphatase SHP2 (encoded by PTPN11), a positive regulator of the RAS signalling pathway, are found in 50% of patients with Noonan syndrome. These patients have an increased risk of developing leukaemia, especially juvenile myelomonocytic leukaemia (JMML), a childhood myeloproliferative neoplasm (MPN). Previous studies have demonstrated that mutations in Ptpn11 induce a JMML-like MPN through cell-autonomous mechanisms that are dependent on Shp2 catalytic activity. However, the effect of these mutations in the bone marrow microenvironment remains unclear. Here we report that Ptpn11 activating mutations in the mouse bone marrow microenvironment promote the development and progression of MPN through profound detrimental effects on haematopoietic stem cells (HSCs). Ptpn11 mutations in mesenchymal stem/progenitor cells and osteoprogenitors, but not in differentiated osteoblasts or endothelial cells, cause excessive production of the CC chemokine CCL3 (also known as MIP-1α), which recruits monocytes to the area in which HSCs also reside. Consequently, HSCs are hyperactivated by interleukin-1β and possibly other proinflammatory cytokines produced by monocytes, leading to exacerbated MPN and to donor-cell-derived MPN following stem cell transplantation. Remarkably, administration of CCL3 receptor antagonists effectively reverses MPN development induced by the Ptpn11-mutated bone marrow microenvironment. This study reveals the critical contribution of Ptpn11 mutations in the bone marrow microenvironment to leukaemogenesis and identifies CCL3 as a potential therapeutic target for controlling leukaemic progression in Noonan syndrome and for improving stem cell transplantation therapy in Noonan-syndrome-associated leukaemias.
Collapse
Affiliation(s)
- Lei Dong
- Department of Pediatrics, Division of Hematology/Oncology, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, Georgia 30322, USA
| | - Wen-Mei Yu
- Department of Pediatrics, Division of Hematology/Oncology, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, Georgia 30322, USA
| | - Hong Zheng
- Department of Pediatrics, Division of Hematology/Oncology, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, Georgia 30322, USA
| | - Mignon L Loh
- Department of Pediatrics, Division of Pediatric Hematology-Oncology, University of California at San Francisco, San Francisco, California 94122, USA
| | - Silvia T Bunting
- Department of Pathology, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia 30322, USA
| | - Melinda Pauly
- Department of Pediatrics, Division of Hematology/Oncology, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, Georgia 30322, USA
| | - Gang Huang
- Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital, University of Cincinnati, Cincinnati, Ohio 45229, USA
| | - Muxiang Zhou
- Department of Pediatrics, Division of Hematology/Oncology, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, Georgia 30322, USA
| | - Hal E Broxmeyer
- Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
| | - David T Scadden
- Center for Regenerative Medicine and MGH Cancer Center, Massachusetts General Hospital, Department of Stem Cell and Regenerative Biology and Harvard Stem Cell Institute, Harvard University, Boston, Massachusetts 02114, USA
| | - Cheng-Kui Qu
- Department of Pediatrics, Division of Hematology/Oncology, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, Georgia 30322, USA
| |
Collapse
|
7
|
Raikar SS, Scarborough JD, Sabnis H, Bergsagel J, Wu D, Cooper TM, Keller FG, Wood BL, Bunting ST. Early T-Cell Precursor Acute Lymphoblastic Leukemia in an Infant With an NRAS Q61R Mutation and Clinical Features of Juvenile Myelomonocytic Leukemia. Pediatr Blood Cancer 2016; 63:1667-70. [PMID: 27145535 DOI: 10.1002/pbc.26050] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/06/2016] [Accepted: 04/18/2016] [Indexed: 11/09/2022]
Abstract
Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is a subtype of T-acute lymphoblastic leukemia (T-ALL) arising from a primitive precursor. We present a unique case of an infant with ETP-ALL with a missense NRAS mutation in codon 61 (c.182A>G, p.Q61R). The patient also had a minor population of non-ETP T-ALL blasts and clinical features typically associated with juvenile myelomonocytic leukemia (JMML), namely, absolute monocytosis, splenomegaly, and elevated hemoglobin F. The treatment was initiated with chemotherapy, followed by cord blood transplantation. The patient achieved remission, but unfortunately died from transplant-related complications. This case highlights an NRAS mutation in ETP-ALL with JMML-like phenotype.
Collapse
Affiliation(s)
- Sunil S Raikar
- Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Emory University, Atlanta, Georgia
| | - John D Scarborough
- Department of Laboratory Medicine, University of Washington, Seattle, Washington
| | - Himalee Sabnis
- Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Emory University, Atlanta, Georgia
| | - John Bergsagel
- Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Emory University, Atlanta, Georgia
| | - David Wu
- Department of Laboratory Medicine, University of Washington, Seattle, Washington
| | - Todd M Cooper
- Department of Pediatrics, Seattle Children's Hospital, Seattle, Washington
| | - Frank G Keller
- Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Emory University, Atlanta, Georgia
| | - Brent L Wood
- Department of Laboratory Medicine, University of Washington, Seattle, Washington
| | - Silvia T Bunting
- Department of Pathology, Children's Healthcare of Atlanta and Emory University, Atlanta, Georgia
| |
Collapse
|
8
|
Wang Z, Medrzycki M, Bunting ST, Bunting KD. Stat5-deficient hematopoiesis is permissive for Myc-induced B-cell leukemogenesis. Oncotarget 2016; 6:28961-72. [PMID: 26338970 PMCID: PMC4745704 DOI: 10.18632/oncotarget.5009] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2015] [Accepted: 08/12/2015] [Indexed: 11/28/2022] Open
Abstract
Despite being an attractive molecular target for both lymphoid and myeloid leukemias characterized by activated tyrosine kinases, the molecular and physiological consequences of reduced signal transducer and activator of transcription-5 (Stat5) during leukemogenesis are not well known. Stat5 is a critical regulator of mouse hematopoietic stem cell (HSC) self-renewal and is essential for normal lymphocyte development. We report that pan-hematopoietic deletion in viable adult Vav1-Cre conditional knockout mice as well as Stat5abnull/null fetal liver transplant chimeras generated HSCs with reduced expression of quiescence regulating genes (Tie2, Mpl, Slamf1, Spi1, Cited2) and increased expression of B-cell development genes (Satb1, Dntt, Btla, Flk2). Using a classical murine B-cell acute lymphoblastic leukemia (B-ALL) model, we demonstrate that these HSCs were also poised to produce a burst of B-cell precursors upon expression of Bcl-2 combined with oncogenic Myc. This strong selective advantage for leukemic transformation in the background of Stat5 deficient hematopoiesis was permissive for faster initiation of Myc-induced transformation to B-ALL. However, once established, the B-ALL progression in secondary transplant recipients was Stat5-independent. Overall, these studies suggest that Stat5 can play multiple important roles that not only preserve the HSC compartment but can limit accumulation of potential pre-leukemic lymphoid populations.
Collapse
Affiliation(s)
- Zhengqi Wang
- Department of Pediatrics, Division of Hematology-Oncology-BMT, Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta and Emory University, Atlanta GA, USA
| | - Magdalena Medrzycki
- Department of Pediatrics, Division of Hematology-Oncology-BMT, Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta and Emory University, Atlanta GA, USA
| | - Silvia T Bunting
- Department of Pathology, Children's Healthcare of Atlanta, Atlanta GA, USA
| | - Kevin D Bunting
- Department of Pediatrics, Division of Hematology-Oncology-BMT, Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta and Emory University, Atlanta GA, USA
| |
Collapse
|
9
|
Guillory T, Li S, Bergsagel DJ, Weinzierl E, Bunting ST. Hematogones With Lambda Light Chain Restriction in a 4-Year-Old Boy With Burkitt Lymphoma: A Potential Diagnostic Pitfall. Lab Med 2016; 47:163-70. [PMID: 27069035 PMCID: PMC4832592 DOI: 10.1093/labmed/lmw009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Hematogones are immature normal B cell precursors with a characteristic immunophenotype profile on flow cytometry that typically do not express surface immunoglobulin light chains. In this report, we describe a case in which the hematogones exhibit light chain restriction. Our patient was a 4-year-old boy with a complicated medical history involving treatment for a presumed bilateral Wilms tumor of the kidney that on later resection was diagnosed as Burkitt lymphoma. Flow cytometry analysis of his bone marrow revealed a small distinct population of cells expressing dim cluster of differentiation (CD)10, CD19, CD22, CD38, dim CD58, human leukocyte antigen-D related (HLA-DR), and dim CD45, which are characteristic of hematogones. These cells, however, demonstrated dim surface immunoglobulin lambda light-chain restriction. Molecular study results for immunoglobulin heavy and kappa light-chain gene rearrangements were negative. We present this case to raise awareness of the potential pitfalls of working up bone marrow for involvement by B cell lymphoproliferative disorder.
Collapse
Affiliation(s)
| | - Shiyong Li
- Department of Pathology, Emory University, Atlanta, GA
| | - Daniel J Bergsagel
- Division of Hematology/Oncology, Department of Pediatrics, AFLAC Cancer and Blood Disorder Center, Emory University, Atlanta, GA
| | - Elizabeth Weinzierl
- Department of Pathology, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA
| | - Silvia T Bunting
- Department of Pathology, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA
| |
Collapse
|
10
|
Park J, Schlederer M, Schreiber M, Ice R, Merkel O, Bilban M, Hofbauer S, Kim S, Addison J, Zou J, Ji C, Bunting ST, Wang Z, Shoham M, Huang G, Bago-Horvath Z, Gibson LF, Rojanasakul Y, Remick S, Ivanov A, Pugacheva E, Bunting KD, Moriggl R, Kenner L, Tse W. AF1q is a novel TCF7 co-factor which activates CD44 and promotes breast cancer metastasis. Oncotarget 2015; 6:20697-710. [PMID: 26079538 PMCID: PMC4653036 DOI: 10.18632/oncotarget.4136] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2015] [Accepted: 04/21/2015] [Indexed: 01/29/2023] Open
Abstract
AF1q is an MLL fusion partner that was identified from acute myeloid leukemia (AML) patients with t (1; 11) (q21; q23) chromosomal abnormality. The function of AF1q is not yet fully known, however, elevated AF1q expression is associated with poor clinical outcomes in various malignancies. Here, we show that AF1q specifically binds to T-cell-factor-7 (TCF7) in the Wnt signaling pathway and results in transcriptional activation of CD44 as well as multiple downstream targets of the TCF7/LEF1. In addition, enhanced AF1q expression promotes breast cancer cell proliferation, migration, mammosphere formation, and chemo-resistance. In xenograft models, enforced AF1q expression in breast cancer cells also promotes liver metastasis and lung colonization. In a cohort of 63 breast cancer patients, higher percentages of AF1q-positive cancer cells in primary sites were associated with significantly poorer overall survival (OS), disease-free survival (DFS), and brain metastasis-free survival (b-MFS). Using paired primary/metastatic samples from the same patients, we demonstrate that AF1q-positive breast cancer cells become dynamically dominant in the metastatic sites compared to the primary sites. Our findings indicate that breast cancer cells with a hyperactive AF1q/TCF7/CD44 regulatory axis in the primary sites may represent "metastatic founder cells" which have invasive properties.
Collapse
Affiliation(s)
- Jino Park
- James Graham Brown Cancer Center, Division of Blood and Bone Marrow Transplantation, Department of Medicine, University of Louisville School of Medicine, Louisville, KY, USA
| | - Michaela Schlederer
- Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria
- Clinical Institute for Pathology, Medical University Vienna, Austria
| | - Martin Schreiber
- Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - Ryan Ice
- Mary Babb Randolph Cancer Center, West Virginia University Health Science Center, Morgantown, WV, USA
- Department of Biochemistry, West Virginia University School of Medicine, Morgantown, WV, USA
| | - Olaf Merkel
- National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany
| | - Martin Bilban
- Department of Laboratory Medicine, Medical University of Vienna and Core Facility Genomics, Core Facilities, Medical University of Vienna, Vienna, Austria
| | - Sebastian Hofbauer
- Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - Soojin Kim
- James Graham Brown Cancer Center, Division of Blood and Bone Marrow Transplantation, Department of Medicine, University of Louisville School of Medicine, Louisville, KY, USA
| | - Joseph Addison
- Mary Babb Randolph Cancer Center, West Virginia University Health Science Center, Morgantown, WV, USA
- Department of Biochemistry, West Virginia University School of Medicine, Morgantown, WV, USA
| | - Jie Zou
- Department of Hematology, Qilu Hospital, Shandong University School of Medicine, Jinan, Shandong, PR China
| | - Chunyan Ji
- Department of Hematology, Qilu Hospital, Shandong University School of Medicine, Jinan, Shandong, PR China
| | - Silvia T. Bunting
- Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta and Emory University School of Medicine, Atlanta, GA, USA
| | - Zhengqi Wang
- Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta and Emory University School of Medicine, Atlanta, GA, USA
| | - Menachem Shoham
- Case Western University School of Medicine, Cleveland, OH, USA
| | - Gang Huang
- Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
| | | | - Laura F. Gibson
- Mary Babb Randolph Cancer Center, West Virginia University Health Science Center, Morgantown, WV, USA
| | - Yon Rojanasakul
- Mary Babb Randolph Cancer Center, West Virginia University Health Science Center, Morgantown, WV, USA
- Department of Pharmaceutical Science, West Virginia University School of Medicine, Morgantown, WV, USA
| | - Scot Remick
- Mary Babb Randolph Cancer Center, West Virginia University Health Science Center, Morgantown, WV, USA
| | - Alexey Ivanov
- Mary Babb Randolph Cancer Center, West Virginia University Health Science Center, Morgantown, WV, USA
- Department of Biochemistry, West Virginia University School of Medicine, Morgantown, WV, USA
| | - Elena Pugacheva
- Mary Babb Randolph Cancer Center, West Virginia University Health Science Center, Morgantown, WV, USA
- Department of Biochemistry, West Virginia University School of Medicine, Morgantown, WV, USA
| | - Kevin D. Bunting
- Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta and Emory University School of Medicine, Atlanta, GA, USA
| | - Richard Moriggl
- Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria
- Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, Medical University of Vienna, Vienna, Austria
| | - Lukas Kenner
- Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria
- Clinical Institute for Pathology, Medical University Vienna, Austria
- Unit of Pathology of Laboratory Animals (UPLA), University of Veterinary Medicine, Vienna, Austria
| | - William Tse
- James Graham Brown Cancer Center, Division of Blood and Bone Marrow Transplantation, Department of Medicine, University of Louisville School of Medicine, Louisville, KY, USA
| |
Collapse
|
11
|
Doshi BS, Abramowsky C, Briones M, Bunting ST. Concomitant a novel ALAS2 mutation and GATA1 mutation in a newborn: a case report and review of the literature. Am J Blood Res 2014; 4:41-45. [PMID: 25232504 PMCID: PMC4165116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 07/11/2014] [Accepted: 08/06/2014] [Indexed: 06/03/2023]
Abstract
GATA-1, an X-linked gene, encodes a transcription factor that plays a role in erythropoiesis and megakaryopoiesis. GATA-1 mutations have been associated with various diseases, such as X-linked thrombocytopenia. ALAS2 is an X-linked erythroid-specific isoenzyme expressed during erythropoiesis. Mutations of ALAS2 were associated with X-linked sideroblastic anemia. We report a case of newborn twin boy with anemia and thrombocytopenia at birth. A bone marrow biopsy at 4 months of age showed marked dyserythropoiesis, dysmegakaryopoiesis, and rare ringed sideroblasts. Gene sequencing study showed a previously reported mutation in GATA-1 at c.622G>A location (G208R) and a novel ALAS2 mutation at c.1436G>A location (R479Q).
Collapse
Affiliation(s)
- Bhavya S Doshi
- Department of Pediatrics, Emory University School of MedicineAtlanta, GA 30322, USA
| | - Carlos Abramowsky
- Department of Pathology, Emory University School of MedicineAtlanta, GA 30322, USA
| | - Michael Briones
- Children’s Healthcare of Atlanta, Aflac Cancer and Blood Disorders CenterAtlanta, GA 30322, USA
| | - Silvia T Bunting
- Department of Pathology, Children’s Healthcare of Atlanta, Emory UniversityAtlanta, GA, 30322, USA
| |
Collapse
|
12
|
Tyburski EA, Gillespie SE, Stoy WA, Mannino RG, Weiss AJ, Siu AF, Bulloch RH, Thota K, Cardenas A, Session W, Khoury HJ, O'Connor S, Bunting ST, Boudreaux J, Forest CR, Gaddh M, Leong T, Lyon LA, Lam WA. Disposable platform provides visual and color-based point-of-care anemia self-testing. J Clin Invest 2014; 124:4387-94. [PMID: 25157824 DOI: 10.1172/jci76666] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2014] [Accepted: 07/24/2014] [Indexed: 11/17/2022] Open
Abstract
BACKGROUND Anemia, or low blood hemoglobin (Hgb) levels, afflicts 2 billion people worldwide. Currently, Hgb levels are typically measured from blood samples using hematology analyzers, which are housed in hospitals, clinics, or commercial laboratories and require skilled technicians to operate. A reliable, inexpensive point-of-care (POC) Hgb test would enable cost-effective anemia screening and chronically anemic patients to self-monitor their disease. We present a rapid, stand-alone, and disposable POC anemia test that, via a single drop of blood, outputs color-based visual results that correlate with Hgb levels. METHODS We tested blood from 238 pediatric and adult patients with anemia of varying degrees and etiologies and compared hematology analyzer Hgb levels with POC Hgb levels, which were estimated via visual interpretation using a color scale and an optional smartphone app for automated analysis. RESULTS POC Hgb levels correlated with hematology analyzer Hgb levels (r = 0.864 and r = 0.856 for visual interpretation and smartphone app, respectively), and both POC test methods yielded comparable sensitivity and specificity for detecting any anemia (n = 178) (<11 g/dl) (sensitivity: 90.2% and 91.1%, specificity: 83.7% and 79.2%, respectively) and severe anemia (n = 10) (<7 g/dl) (sensitivity: 90.0% and 100%, specificity: 94.6% and 93.9%, respectively). CONCLUSIONS These results demonstrate the feasibility of this POC color-based diagnostic test for self-screening/self-monitoring of anemia. TRIAL REGISTRATION Not applicable. FUNDING This work was funded by the FDA-funded Atlantic Pediatric Device Consortium, the Georgia Research Alliance, Children's Healthcare of Atlanta, the Georgia Center of Innovation for Manufacturing, and the InVenture Prize and Ideas to Serve competitions at the Georgia Institute of Technology.
Collapse
|
13
|
Sabnis H, Bradley HL, Bunting ST, Cooper TM, Bunting KD. Capillary nano-immunoassay for Akt 1/2/3 and 4EBP1 phosphorylation in acute myeloid leukemia. J Transl Med 2014; 12:166. [PMID: 24923301 PMCID: PMC4080754 DOI: 10.1186/1479-5876-12-166] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2014] [Accepted: 05/14/2014] [Indexed: 11/16/2022] Open
Abstract
Background Overall cure rates in acute myeloid leukemia (AML) continue to range between 60-65% with disease relapse being a major cause of mortality. The PI3K-Akt-mTOR kinase pathway plays a vital role in pro-survival signals within leukemic cells and inhibition of this pathway is being investigated to improve patient outcomes. Tracking activation of multiple signaling proteins simultaneously in patient samples can be challenging especially with limiting cell numbers within rare sub-populations. Methods The NanoPro 1000 system (ProteinSimple) is built on an automated, capillary-based immunoassay platform and enables a rapid and quantitative analysis of specific proteins and their phosphorylation states. We have utilized this nano-immunoassay to examine activation of Akt 1/2/3 and downstream mTOR target - eukaryotic initiation factor 4E-Binding Protein 1 (4EBP1). Results Assays for Akt 1/2/3 and 4EBP1 were standardized using AML cell lines (MV4-11, MOLM-14, OCI-AML3 and HL-60) prior to testing in patient samples. Target inhibition was studied using mTOR 1/2 inhibitor AZD-8055 and results were corroborated by Western blotting. The assay was able to quantify nanogram amounts of 4EBP1 and Akt 1/2/3 in AML cell lines and primary pediatric AML samples and results were quantifiable, consistent and reproducible. Conclusion Our data provides a strong basis for testing this platform on a larger scale and our long term aim is to utilize this nano-immunoassay prospectively in de-novo AML to be able to identify poor responders who might benefit from early introduction of targeted therapy.
Collapse
Affiliation(s)
| | | | | | | | - Kevin D Bunting
- Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University, 1760 Haygood Drive NE, Atlanta, Georgia, USA.
| |
Collapse
|
14
|
Liang X, Russell SR, Estelle S, Jones LH, Cho S, Kahn ML, Berndt MC, Bunting ST, Ware J, Li R. Specific inhibition of ectodomain shedding of glycoprotein Ibα by targeting its juxtamembrane shedding cleavage site. J Thromb Haemost 2013; 11:2155-62. [PMID: 24119228 PMCID: PMC3947459 DOI: 10.1111/jth.12425] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2013] [Accepted: 09/29/2013] [Indexed: 11/27/2022]
Abstract
BACKGROUND Ectodomain shedding of glycoprotein Ibα (GPIbα), a proteolytic event in which metalloprotease ADAM17 cleaves the Gly464-Val465 bond and releases glycocalicin to the plasma, is considered a critical step in mediating clearance of stored platelets. Supporting evidence has largely come from studies using ADAM17 inhibitors. However, the definitive proof is lacking due to the broad substrate specificity of ADAM17. AIM To achieve substrate-specific inhibition of GPIbα shedding. METHODS Development of monoclonal antibodies that directly bind the sequence around the GPIbα shedding cleavage site and inhibit GPIbα shedding by blocking ADAM17 access to the cleavage site. RESULTS Six anti-GPIbα monoclonal antibodies with varying binding affinities were obtained. The prototypic clone, designated 5G6, and its monomeric Fab fragment bind specifically purified GPIb-IX complex, human platelets, and transgenic murine platelets expressing human GPIbα. The clone 5G6 showed similar inhibitory potency as a widely used shedding inhibitor GM6001 in both constitutive and induced GPIbα shedding in human platelets. It does not recognize mouse GPIbα or inhibit shedding of other platelet receptors. Finally, 5G6 binding displays no detectable effect on platelet activation and aggregation. CONCLUSIONS The clone 5G6 specifically inhibits GPIbα shedding with no detectable effect on platelet functions. The method of substrate-specific shedding inhibition by macromolecular binding of the shedding cleavage site can be applicable to many other transmembrane receptors undergoing ectodomain shedding.
Collapse
Affiliation(s)
- Xin Liang
- Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA
| | - Susan R. Russell
- Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, AR
| | - Sandra Estelle
- Department of Pathology, Children’s Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA
| | - Limei H. Jones
- Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA
| | - Sungyun Cho
- Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA
| | - Mark L. Kahn
- Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
| | - Michael C. Berndt
- Faculty of Health Sciences, Curtin University, Perth, Western Australia, Australia
| | - Silvia T. Bunting
- Department of Pathology, Children’s Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA
| | - Jerry Ware
- Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA
| | - Renhao Li
- Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA
| |
Collapse
|
15
|
Affiliation(s)
- Silvia T Bunting
- Department of Pathology, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia 30322
| |
Collapse
|